Updates in the Pharmacotherapy of COPD (CTS)
March 22, 2018 - Learn more about the new COPD personalized treatment proposed by the recent publication of the Canadian Thoracic Society (CTS).
The Canadian Thoracic Society has recently published an update on the pharmacotherapy in patients with COPD. This new position statement is a must read for anyone providing care and working with people affected by COPD.
This position statement is an evolution towards personalized treatment, compared to the previous published CTS COPD guideline. It promotes approaches to match treatment decisions based on symptom burden and risk of future exacerbations. It also presents key messages which best reflects the practice in Canada on the assessment, diagnosis and pharmacotherapy of patients who have COPD with features of asthma also known as Asthma/COPD Overlap (ACO).
Bourbeau J, Bhutani M, Hernandez P et al. CTS position statement: Pharmacotherapy in patients with COPD—An update. CJRCCSM 2017, VOL. 1, NO. 4, 222–241 |
What you will get after consulting the new CTS Position Statement in COPD
|
Click here to access the full CTS position statement on COPD.
Remember: Full access to this publication is free for members of the Canadian Thoracic Society (CTS) and the Canadian Respiratory Health Professionals (CRHP). There are many benefits to joining including:
- Free online subscription to the Canadian Respiratory Journal
- Free educational webinars
- Discounted registration fee for the Canadian Respiratory Conference
- And many more!
To learn more about the CTS and the CRHP memberships, click here
Back to list